Pituitary disorders:

Indications for: SIGNIFOR LAR

Treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option.

Adult Dosage:

Give by IM inj into the right or left gluteus. Initially 40mg every 4 weeks (28 days); may increase dose to max 60mg after 3 months if GH and/or IGF-1 levels not normalized. If over-response to treatment, may decrease in 20mg decrements. Hepatic impairment: moderate (Child-Pugh B): initially 20mg every 4 weeks; max: 40mg every 4 weeks; severe (Child-Pugh C): avoid.

Children Dosage:

<18yrs: not established.

SIGNIFOR LAR Warnings/Precautions:

Monitor for adrenal insufficiency; give steroid replacement therapy if confirmed. Risk of hyperglycemia; initiate or adjust antidiabetic treatment if occurs; reduce Signifor LAR or discontinue if remains uncontrolled. Monitor HbA1c and FPG prior to initiation, weekly for first 3 months, 4–6 weeks after dose increase, and thereafter as indicated. Monitor for ketoacidosis; if suspected, discontinue and evaluate promptly. Congenital long QT prolongation. Cardiac disease (eg, recent MI, CHF, unstable angina, significant bradycardia); monitor QT interval at 21 days. High-grade heart block. Hypokalemia and/or hypomagnesemia; correct and monitor electrolytes prior to starting and during therapy. Monitor liver tests prior to initiation, 2–3 weeks after, then monthly for 3 months, then as indicated. Discontinue if significant hepatic impairment develops. Monitor baseline ECG, pituitary function prior to initiation and periodically during treatment. Discontinue and treat if cholelithiasis complications are suspected. Renal impairment: not studied. Premenopausal women: potential for unintended pregnancy due to improved fertility. Pregnancy. Nursing mothers.

SIGNIFOR LAR Classification:

Cyclohexapeptide somatostatin analog.

SIGNIFOR LAR Interactions:

Caution with antiarrhythmics or other drugs that may prolong the QT interval. May antagonize cyclosporine (adjust dose). May potentiate bromocriptine; dose reduction may be needed.

Adverse Reactions:

Diarrhea, hyperglycemia, diabetes, cholelithiasis (monitor); bradycardia, QT prolongation, pituitary hormone deficiency.

Generic Drug Availability:


How Supplied:

Single-use kit—1 (w. diluents, supplies)